Genesis Capital has acquired a 75% stake in Czech healthcare research and regulatory service Quinta-Analytica.
Genesis's buyout is part of the company's succession plan. The remaining 25% stake is held by two managers who will lead the company. One of the founders, Miroslav Ryska, will stay on for a limited transition period as member of the supervisory board.
Quinta's customer base is mainly located in central and eastern Europe. The business hopes to further internationalise its customer base and to grow through add-on acquisitions of small and medium-sized companies in Europe, in areas that could complement its activities in pre-clinical and clinical studies as well as pharmaceutical analysis.
It will also expand its services related to bioanalytical laboratory and drug quality control for pharmaceutical producers and drug importers in new territories. Quinta hopes to enter the area of original drugs and laboratory services related to the research of large molecules in the future.
The acquisition marks the first deal for Genesis Private Equity Fund III, which secured €80m in commitments and invests in small and medium-sized enterprises in the Czech Republic and Slovakia.
Founded in 1997 and based in Prague, Quinta provides commercial services for the pharmaceutical, biotechnology and generic drug industries as a contract research organisation.
The company employs 130 people. In 2015, its sales reached CZK 256m.
Genesis Capital – Jan Tauber (managing partner).
Quinta-Analytica – Marika Pečená (managing partner).